Urologic medications and ophthalmologic side effects: A review

Journal of the Canadian Urological Association

Volumn 6, Issue 1, 2012, Pages 53-58

  Gani, Johan ^a   Perlis, Nathan ^a   Radomski, Sidney B ^a  

^a TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84857308138     PISSN: 19116470     EISSN: None     Source Type: Journal    
DOI: 10.5489/cuaj.11037     Document Type: Review

References (55)

1. Jacobsen SJ, Girman CJ, Guess HA, et al. New Diagnostic and treatment guidelines for benign prostatic hyperplasia. Arch Intern Med 1995;155:477-81.http://dx.doi.org/10.1001/ archinte.1995.00430050053006
2. Chute CG, Panser LA, Girman CJ, et al. The prevalence of prostatism: a population based survey of urinary tract symptoms. J Urol 1993;150:85-9.
3. Williams A, Sloan FA, Lee PP. Longitudinal rates of cataract surgery. Arch Ophthalmol 2006;124:1308-14.http://dx.doi.org/10.1001/archopht.124.9.1308
4. Chang DF, Campbell JR. Intraoperative floppy iris syndrome associated with tamsulosin. J Cataract Refract Surg 2005;31:664-73.http://dx.doi.org/10.1016/j.jcrs.2005.02.027
5. Bell CM, Hatch WV, Fischer WV, et al. Association between tamsulosin and serious ophthalmic adverse events in older men following cataract surgery. JAMA 2009;301:1991-6.http://dx.doi.org/10.1001/jama.2009.683
6. Chang DF, Osher RH, Wang L, et al. A prospective multicenter evaluation of cataract surgery in patients taking tamsulosin (Flomax). Ophthalmology 2007;114:957-64.http://dx.doi.org/10.1016/j.ophtha.2007.01.011
7. Chadha V, Borooah S, Tey A, et al. Floppy Iris behavior during cataract surgery: associations and variations. Br J Ophthalmol 2007;91:40-2.http://dx.doi.org/10.1136/bjo.2006.103036
8. Blouin MC, Blouin J, Perreault S, et al. Intraoperative floppy-iris syndrome associated with alpha 1-adrenoceptors comparison of tamsulosin and alfuzosin. J Cataract Refract Surg 2007;33:1227-34.http:// dx.doi.org/10.1016/j.jcrs.2007.03.032
9. Keklikci U, Isen K, Unlu K, et al. Incidence, clinical findings and management of intraoperative floppy iris syndrome associated with tamsulosin. Acta Ophthalmol 2009;87:306-9.http://dx.doi.org/10.1111/j.1755-3768.2008.01246.x
10. Altan-Yaycioglu R, Gedik S, Pelit A, et al. Clinical factors associated with floppy iris signs: a prospective study from two centers. Ophthalmic Surg Lasers Imaging 2009;40:232-8.http://dx.doi.org/10.3928/15428877-20090430-02
11. Takmaz T, Can I. Clinical features, complications and incidence of floppy iris syndrome in patients taking tamsulosin. Eur J Ophthalmol 2007;17:909-13.
12. Oshika T, Ohashi Y, Inamura M, et al. Incidence of intraoperative floppy iris syndrome in patients on either systemic or topical alpha1-adrenoceptor antagonists. Am J Ophthalmol 2007;143:150-1 http://dx.doi.org/10.1016/j.ajo.2006.07.046
13. Neff KD, Sandoval HP, de Castro LEF, et al. Factors associated with intraoperative floppy iris syndrome. Ophthalmology 2009;116:658-63.http://dx.doi.org/10.1016/j.ophtha.2008.12.026
14. Cheung CM, Awan MA, Peh KK, et al. Comment on: incidence of intraoperative floppy iris syndrome in patients on either systemic or topical alpha 1 adrenoceptor antagonists. Am J Ophthalmol 2007;143:1070-1. http://dx.doi.org/10.1016/j.ajo.2007.02.044
15. Srinivasan S, Radomski S, Chung J, et al. Intraoperative floppy iris syndrome during cataract surgery in men using alpha blockers for benign prostatic hypertrophy. J Cataract Refract Surg 2007;33:1826-7.http://dx.doi.org/10.1016/j.jcrs.2007.06.033
16. Issa SA, Hadid OH, Baylis O, et al. Alpha antagonists and intraoperative floppy iris syndrome: A Spectrum. Clin Ophthalmol 2008;2:735-41.http://dx.doi.org/10.2147/OPTH.S2697
17. Cantrell MA, Bream-Rouwenhorst HR, Steffensmeier A, et al. Intraoperative floppy iris syndrome associated with alpha 1-adrenergic receptor antagonists. Ann Pharmacother 2008;42:558-63.http://dx.doi.org/10.1345/aph.1K679
18. Prata TS, Palmiero PM, Angelilli A, et al. Iris morphologic changes related to alpha one adrenergic receptor antagonists: implications for floppy iris syndrome. Ophthalmology 2009;116:877-81.http://dx.doi. org/10.1016/j.ophtha.2008.12.040
19. Shah N, Tendulkar M, Brown R. Should we anticipate intraoperative floppy iris syndrome (IFIS) even with very short history of tamsulosin? Eye 2009;23:740. http://dx.doi.org/10.1038/eye.2008.95
20. Chang DF, Braga-Mele R, Mamalis N, et al. ASCRS white paper: clinical review of intraoperative floppy-iris syndrome. J Cataract Refract Surg 2008;34:2153-62.http://dx.doi.org/10.1016/j.jcrs.2008.08.031
21. Ugarte M, Leong T, Russam S, et al. Intraoperative floppy-iris syndrome, alpha1-adrenergic antagonists, and chronic intake of mianserin: is there an association? J Cataract Refract Surg 2007;33:170-1.http://dx.doi.org/10.1016/j.jcrs.2006.07.047
22. Pringle E, Packard R. Antipsychotic agents as an etiologic agent of IFIS. J Cataract Refract Surg 2005;31:2240-1.http://dx.doi.org/10.1016/j.jcrs.2005.12.066
23. Calotti F, Steen D. Labetalol causing introperative floppy iris syndrome. J Cataract Refract Surg 2007;33:170. http://dx.doi.org/10.1016/j.jcrs.2006.07.048
24. Yeu E, Grostern R. Saw palmetto and intraoperative floppy-iris syndrome. J Cataract Refract Surg 2007;33:927-8.http://dx.doi.org/10.1016/j.jcrs.2006.12.032
25. Issa SA, Dagres E. Intraoperative floppy-iris syndrome and finastride intake. J Cataract Refract Surg 2007;33:2142-3.http://dx.doi.org/10.1016/j.jcrs.2007.07.025
26. Schwinn DA, Afshari NA. Alpha 1 - Adrenergic receptor antagonists and the iris: new mechanistic insights into floppy iris syndrome. Surv Ophtlmol 2006;51:501-12.http://dx.doi.org/10.1016/j.survophthal.2006.06.011
27. Abrams P, Kaplan S, De HJ, et al. Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J Urol 2006;175:999-1004.http://dx.doi.org/10.1016/S0022-5347(05)00483-0
28. Kaplan SA, Roehrborn CG, Rovner ES, et al. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA 2006;296:2319-28.http://dx.doi.org/10.1001/jama.296.19.2319
29. U.S. Food and Drug Administration. Safety Alert: Flomax (tamsulosin) HCL. 2005 www.fda.gov/safety (Accessed February 1, 2012).
30. Nguyen DQ, Sebastian RT, Kyle G. Surgeon's experiences of the intraoperative floppy iris syndrome in the United Kingdom. Eye 2007;21:443-4.http://dx.doi.org/10.1038/sj.eye.6702616
31. Osher RH. Association between IFIS and flomax. J Cataract Refract Surg 2006;32:547. http://dx.doi.org/10.1016/j.jcrs.2006.01.008
32. Lawrentschuk N, Bylsma GW. Intraoperative "floppy iris" syndrome and its relationship to tamsulosin: a urologists guide. BJU Int 2006;97:2-4.http://dx.doi.org/10.1111/j.1464-410X.2006.05960.x
33. Nguyen DQ, Sebastian RT, Philip J. Intraoperative floppy iris syndrome associated with tamsulosin. BJU Int 2006;97:197. http://dx.doi.org/10.1111/j.1464-410X.2006.06049_1.x
34. Issa MM, Lin PJ, Eaddy MT, et al. Comparative analysis of alpha-blocker utilization in combination with 5-alpha reductase inhibitors for enlarged prostate in a managed care setting among Medicare-aged men. Am J Manag Care 2008;14(5 Suppl2):S160-6.
35. Barkin J, Guimaraes M, Jacobi G, et al. Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5 alpha-reductase inhibitor dutasteride. Eur Urol 2003;44:461-6.http://dx.doi.org/10.1016/S0302-2838(03)00367-1
36. Hattenhauer MG, Leavitt JA, Hodge DO, et al. Incidence of nonarteritic anterior ischemic optic neuropathy. Am J Ophthalmol 1997;123:103-7.
37. Newman NJ, Scherer R, Langenberg P, et al. Ischemic Optic Neuropathy Decompression Trial Research Group. The fellow eye in NAION: report from the ischemic optic neuropathy decompression trial follow-up study. Am J Ophthalmol 2002;134:317-28.http://dx.doi.org/10.1016/S0002-9394(02)01639-2
38. Hayreh SS, Zimmerman MB. Non-arteritic anterior ischemic optic neuropathy: role of systemic corticosteroid therapy. Graefes Arch Clin Exp Ophthalmol 2008;246:1029-46.Epub 2008 Apr 11.
39. Sohn BJ, Chun BY, Kwon JY. The effect of an intravitreal triamcinolone acetonide injection for acute nonarteritic anterior ischemic optic neuropathy. Korean J Ophthalmol 2009;23:59-61.http://dx.doi.org/10.3341/kjo.2009.23.1.59
40. Yaman A, Selver OB, Saatci AO, et al. Intravitreal triamcinolone acetonide injection for acute non-arteritic anterior ischemic optic neuropathy. Clin Exp Optom 2008;91:561-4.http://dx.doi.org/10.1111/j.1444-0938.2008.00287.x
41. The Ischemic Optic Neuropathy Decompression Trial Research Group. Optic nerve decompression surgery for nonarteritic anterior ischemic optic neuropathy (NAION) is not effective and may be harmful. JAMA 1995;273:625-32.http://dx.doi.org/10.1001/jama.1995.03520320035038
42. McGwin GJ, Vaphiades M, Hall T, et al. Non-arteritic anterior ischemic optic neuropathy and the treatment of erectile dysfunction. Br J Ophthalmol 2006;90:154-7.http://dx.doi.org/10.1136/bjo.2005.083519
43. Hazell L, Cornelius V, Wilton LV, et al. The safety profile of tadalafil as prescribed in general practice in England: results from a prescription-event monitoring study involving 16 129 patients. BJU Int 2009;103:506-14.http://dx.doi.org/10.1111/j.1464-410X.2008.08000.x
44. Giuliano F, Jackson G, Montorsi F, et al. Safety of sildenafil citrate: review of 67 double-blind placebocontrolled trials and the post-marketing safety database. Int J Clin Pract 2010;64:240-55.http://dx.doi.org/10.1111/j.1742-1241.2009.02254.x
45. Gorkin L, Hvidsten K, Sobel RE, et al. Sildenafil citrate use and the incidence of nonarteritic anterior ischemic optic neuropathy. Int J Clin Pract 2006;60:500-3.http://dx.doi.org/10.1111/j.1368-5031.2006.00904.x
46. Bella AJ, Brant WO, Lue TF, et al. Non-arteritic anterior ischemic optic neuropathy (NAION) and phosphodiesterase type-5 inhibitors. Can J Urol 2006;13:3233-8.
47. Andersson K, Wein A. Pharmacologic Management of Storage and Emptying Failure. Campbell-Walsh Urology. Alan J. Wein, editor. Philadelphia: PA: Saunders Elsevier, 2007;2091-123.
48. Lachkar Y, Bouassida W. Drug-Induced Acute Angle Closure Glaucoma. Curr Opin Ophthalmol 2007;18:129-33. http://dx.doi.org/10.1097/ICU.0b013e32808738d5
49. Sung V, Corridan P. Acute-Angle Closure Glaucoma as a Side-Effect of Oxybutynin. Br J Urol 1998;81:634-5. http://dx.doi.org/10.1046/j.1464-410x.1998.00403.x
50. Subank-Sharpe I, Low S, Nolan W, et al. Pharmacological and Environmental Factors in Primary Angle- Closure Glaucoma. Br Med Bull 2010; 93:125-43.http://dx.doi.org/10.1093/bmb/ldp042
51. Appell R, Sand P, Dmochowski R, et al. Prospective Randomized Controlled Trial of Extended-Release Oxybutynin Chloride and Tolterodine Tartrate in the Treatment of Overactive Bladder: Results of the OBJECT Study. Mayo Clin Proc 2001;76:358-63.
52. Diokno A, Appell RA, Sand PK, et al. Prospective, Randomized, Double-Blind Study of the Efficacy and Tolerability of the Extended-Release Formulations of Oxybutynin and Tolterodine for Overactive Bladder: Results of the OPERA Trial. Mayo Clin Proc 2003;78:687-95.http://dx.doi.org/10.4065/78.6.687
53. Sussman D, Garely A. Treatment of Overactive Bladder with Once-daily Extended-release Tolterodine or Oxybutynin: The Antimuscarinic Clinical Effectiveness Trial (ACET). Curr Med Res Opin 2002;18:177-84.http://dx.doi.org/10.1185/030079902125000570
54. Altan-Yaycioglu R, Yaycioglu O, Aydin Akova Y, et al. Ocular Side-Effects of Tolterodine and Oxybutynin, a Single-Blind Prospective Randomized Trial. Br J Clin Pharmacol 2005;59:588-92.http://dx.doi.org/10.1111/j.1365-2125.2005.02356.x
55. Kato K, Yoshida K, Suzuki K, et al. Managing Patients with an Overactive Bladder and Glaucoma: A Questionnaire Survey of Japanese Urologists on the Use of Anticholinergics. BJU Int 2005;95:98-101.http://dx.doi.org/10.1111/j.1464-410X.2004.05259.x